Cat. No. 3388
No more than 1 g per individual per year to be sold without prior permission from the license holder.
Alternative Name: ZD1033
Chemical Name: α1,α1,α3,α3-Tetramethyl-5-(1H-1,2,4-tri
Biological ActivityPotent and highly selective aromatase (CYP19) inhibitor (IC50 = 15 nM) that has no discernible effect on adrenocorticoid hormone synthesis. Reduces plasma estrogen levels and exhibits antitumor activity in vivo. Orally active.
Licensing InformationSold for research purposes only under agreement from AstraZeneca
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Buzda (2001) Anastrozole (ArimidexTM) - an aromatase inhibitor for the adjuvant setting? Br.J.Cancer 85 6. PMID: 11900212.
Goss and Tye (1997) Anastrozole: a new selective nonsteroidal aromatase inhibitor. Oncology 11 1697. PMID: 9394367.
Dukes et al (1996) The preclinical pharmacology of "Arimidex" (anastrozole; ZD1033)-a potent, selective aromatase inhibitor. J.Steroid Biochem.Mol.Biol. 58 439. PMID: 8903429.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Anastrozole from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Anastrozole, supplier, Potent, aromatase, CYP19, inhibitors, inhibits, ERR, Estrogen, Receptors, Cytochrome, P450, AstraZeneca, ZD, 1033, Tocris Bioscience, Cytochrome P450 Inhibitor products
Find multiple products by catalog number
New Products in this Area
HIF-prolyl hydroxylase-2 (PHD2) inhibitor; antioxidantpCPA methyl ester hydrochloride
Tryptophan hydroxylase inhibitor
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.